Fitch Upgrades Teva to Investment Grade Following Pivot to Growth
Fitch Ratings has raised Teva Pharmaceutical Industries' credit rating to BBB- with a stable outlook, marking the company's third upgrade in less than two years and its return to investment grade
Teva Pharmaceutical Industries Ltd. announced on May 18, 2026, that Fitch Ratings has upgraded the company's corporate credit rating to investment grade. The rating was raised to BBB- from its previous speculative-grade position of BB+, with Fitch also assigning a stable outlook. This announcement, issued from the company's headquarters in Tel Aviv, Israel, marks a significant shift in the financial standing of the pharmaceutical giant, which is dual-listed on the New York Stock Exchange and the Tel Aviv Stock Exchange.[1][2]
This upgrade is the third time Fitch Ratings has raised Teva's credit profile in less than two years, reflecting a period of consistent financial improvement. The company attributed the rating increase to the successful execution of its Pivot to Growth strategy, which focuses on operational efficiency and expanding its market presence. Leadership stated that the endorsement from Fitch underscores the company's progress in stabilizing its balance sheet and transitioning toward long-term growth execution.[1][2]
